Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Competition Body Backs Up Claim That Pfizer & Flynn Abused Dominant Position With ‘Excessive’ Prices

Executive Summary

The UK CMA has explained why it believes Pfizer and Flynn Pharma abused a dominant market position by charging “excessive and unfair” prices for a generic epilepsy drug, while the two companies have laid out their the grounds for appealing against the decision.

You may also be interested in...

Court Ruling On Pfizer Price Hikes Could Delay Other Investigations, Warns UK Competition Authority

Ongoing Investigations into drug price increases could be at risk following a tribunal ruling in the UK phenytoin sodium case, according to the Competition and Markets Authority, which is considering an appeal against the judgment.

UK Fine For Pfizer/Flynn’s ‘Excessive And Unfair’ Pricing Sends Clear Message To Others

The UK competition authority has fined Pfizer and Flynn Pharma a total of £90m for charging “excessive and unfair” prices for phenytoin sodium capsules; Pfizer has said it will appeal. With an earlier CMA decision to impose a hefty fine on GlaxoSmithKline for its part in a pay-for-delay deal, companies should pay careful consideration to any competition issues raised by their pricing strategies for marketed drugs.

Three Major Regulators Launch Pilot To Reduce Duplication Of GMP Inspections

Regulatory bodies from Australia, Canada and the UK say a new pilot program will reduce the need for multiple inspections of the same site, while an MoU signed by Australia and Canada will cut the amount of documentary evidence required from drug sponsors seeking GMP clearances. 


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts